ClinicalTrials.gg
RecruitingNCT06601465CONVERGE-HFUpdated Aug 25, 2026

COgnitioN With VERiciGuat Evaluation in Heart Failure

A Phase 2 interventional study of Vericiguat in Heart Failure and Cognitive Impairment, sponsored by University of Alberta. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by University of Alberta · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing vericiguat in Heart Failure — 7 open to participants now, 8 under way, 1 of them phase 3. vericiguat · Heart Failure.

Planned enrollment
11th of 19
120 · median 130
Started
2025
with 2 others
Phase 2
5 of 19
1 open now
Registered
14th of 19
by date
Lead sponsor
1 of 19
University of Alberta

Among the 19 studies testing vericiguat in Heart Failure, this one is the 11th largest by planned enrollment, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 14th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 19 studies testing vericiguat in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About vericiguat

vericiguat: first FDA approval 2021 (VERQUVO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing vericiguat in Heart Failure, or all of them as a file.
02

Study summary

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Read the detailed description

CONVERGE-HF is a randomized, open label, phase IIb trial evaluating the effect of sGC stimulator, Vericiguat versus standard of care on imaging markers and blood markers of cerebral and coronary small vessel diseases, function status, cognitive status, quality of life and clinical events in patients with heart failure and mild-to-moderate cognitive impairment. Patients will be randomized and allocated to either vericiguat or standard of care, for 26 weeks including the greater than 4 weeks timeframe for the uptitrations to the target dose.

03

Conditions studied

  • Heart Failure
  • Cognitive Impairment

Keywords

  • Heart Failure
  • Cognitive Impairment
  • Vericiguat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients
  2. Established chronic heart failure (≥ 6 months)
  3. Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a (MoCA) score 10-25).

Exclusion criteria

Exclusion Criteria:

  1. Patients who have for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
  2. Unable to undergo CMR imaging or brain MRI.
  3. CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
  4. General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures [coronary angioplasty and/or surgical revascularization in the previous 3 months], cancer/, or with severe dementia).
  5. Patients with allergies to the study products.
  6. Patients currently hospitalized.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Vericiguat

    A starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. Uptitrated gradually every 2 weeks to 5 mg daily and then to the target dose of 10 mg daily.

    Drug: Vericiguat

  • No intervention
    Standard of Care

    Conventional management of heart failure and mild-to-moderate cognitive impairment.

Interventions

  • Tablet - 2.5 mg, 5 mg, 10 mg

    Also known as: Verquvo

06

What researchers measure

Primary outcomes

  1. Change in the lateral ventricular volumes.

    To determine whether in patients with heart failure and mild-to-moderate cognitive impairment, the 26 weeks of treatment with sGC stimulator, vericiguat versus standard of care lead to greater reduction (or smaller increase) in lateral ventricular volume in brain MRI as a proxy for the preservation of brain microvasculature and preventing brain tissue loss.

    Time frame: 26 weeks

Secondary outcomes

  1. Blood Biomarkers (a)

    To determine the difference in the change in cardiac ischemia and strain markers measured by cardiac troponin, IGFBP-7, and NT-proBNP between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care.

    Time frame: 26 weeks

  2. Blood Biomarkers (b)

    To determine the difference in the change of brain-related marker of cis p-tau between patients with chronic CV disease and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care.

    Time frame: 26 weeks

  3. Imaging Biomarkers (Cardiac)

    To determine the difference between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat, versus standard of care in terms of the change in CMR perfusion test results for perfusion deficits indicative of coronary microvascular impairment.

    Time frame: 26 weeks

  4. Imaging Biomarkers (Brain)

    To determine the difference between patients with heart failure and mild-to-moderate cognitive impairment who were treated for 26 weeks with sGC stimulator, vericiguat versus standard of care in terms of the change in brain MRI peak skeletonized mean diffusivity of the white matter and change in white matter hypersensitivity volume indicative of cerebral small vessel disease.

    Time frame: 26 weeks

  5. Clinical and patient-reported outcomes (MoCA)

    To compare the change of MoCA scores in 26 weeks between groups who were treated with vericiguat versus standard of care.

    Time frame: 26 weeks

  6. Clinical and patient-reported outcomes (KCCQ-12)

    To compare the change of health-related quality of life (assessed via KCCQ-12) in 26 weeks between groups who were treated with vericiguat versus standard of care. The KCCQ-12 has a standardized format and has been validated for paper, electronic or telephone delivery.

    Time frame: 26 weeks

  7. Clinical and patient-reported outcomes (6MWT)

    To compare the change of functional status assessed via 6-minute walk test (6MWT) in 26 weeks between groups who were treated with vericiguat versus standard of care. The 6MWT will be performed as outlined by the American Thoracic Society by an assessor blinded to treatment allocation.61 6MWT will be assessed both in-person and using the validated virtual approach utilizing Walk.Talk.Track app.

    Time frame: 26 weeks

  8. Clinical and patient-reported outcomes (RBANS)

    To compare the change of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores between groups. The RBANS is a widely-used battery for identifying and characterizing abnormal cognitive decline in elderly adults. Its level of difficulty is appropriate for the range from normal cognition to moderately severe dementia.

    Time frame: 26 weeks

  9. Clinical events - Death

    (all cause)

    Time frame: 26 weeks

  10. Clinical events - Hospitalizations

    (all cause)

    Time frame: 26 weeks

  11. Clinical events - Emergency Department Visits

    (all cause)

    Time frame: 26 weeks

  12. Clinical events - Stroke

    Time frame: 26 weeks

  13. Clinical events - Other

    Time frame: 26 weeks

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There are no plans to share IPD at this time.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 37 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 37 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Jun 3, 2025
Primary completionEst.
Jul 16, 2028
CompletionEst.
Jul 16, 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06601465
Collaborators
Ottawa Heart Institute Research Corporation, Heart and Stroke Foundation of Canada
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Jun 3, 2025
Primary completion
Jul 16, 2028 (estimated)
Completion
Jul 16, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Justin Ezekowitz, MBBCh, MSc
Contact
jae2@ualberta.ca
780-492-0712
Amanda Perreault, MSc
Contact
aperreau@ualberta.ca
780-492-5484
Justin Ezekowitz, MBBCh, MSc
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vericiguat

Start the discussion